PMID- 1605430
OWN - NLM
STAT- MEDLINE
DCOM- 19920714
LR  - 20191210
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 117
IP  - 2
DP  - 1992 Jul 15
TI  - Leukocyte reduction in blood component therapy.
PG  - 151-62
AB  - PURPOSE: To review methods of preventing or minimizing the adverse effects 
      associated with the transfusion of passenger leukocytes present in cellular blood 
      components and to define groups of patients who are at risk for adverse effects. 
      DATA SOURCES: English-language articles on transfusion medicine. STUDY SELECTION: 
      Original reports describing the pathogenesis of leukocyte-induced adverse effects 
      in transfusion recipients and the influence of leukocyte-reduced blood components 
      on these effects. DATA EXTRACTION: Evaluation of the diagnosis, transfusion 
      history, and treatment of the study patients; the methods and results of 
      leukocyte reduction; and specific outcomes, including development of 
      alloimmunization to leukocytes, febrile reactions to transfusion, and platelet 
      refractoriness. DATA SYNTHESIS: Passenger leukocytes are the chief cause of 
      alloimmunization to human leukocyte antigen (HLA) and leukocyte-specific antigens 
      in transfusion recipients. Alloimmunization may result in febrile transfusion 
      reactions, platelet refractoriness, and acute lung injury. Leukocytes are also 
      the vector for transfusion-associated cytomegalovirus infection. Technologic 
      advances in the leukocyte reduction of cellular blood components have made it 
      possible to reduce the number of leukocytes to fewer than 10(7) per transfusion. 
      Findings suggest that the use of leukocyte-reduced cellular blood components may 
      minimize or prevent recurrent febrile reactions and alloimmunization to leukocyte 
      antigens. Cytomegalovirus may not be transmitted by blood components containing 
      fewer than 10(7) leukocytes. CONCLUSIONS: Leukocyte reduction in red blood cell 
      and platelet transfusions using third-generation filters is indicated for 
      selected patients who are likely to receive long-term transfusion support, to 
      prevent recurrent febrile reactions and to prevent or delay alloimmunization to 
      leukocyte antigens. Leukocyte-depleted transfusions may also be indicated to 
      delay or prevent refractoriness to platelet transfusion.
FAU - Lane, T A
AU  - Lane TA
AD  - UCSD School of Medicine, Department of Pathology, La Jolla 92093.
FAU - Anderson, K C
AU  - Anderson KC
FAU - Goodnough, L T
AU  - Goodnough LT
FAU - Kurtz, S
AU  - Kurtz S
FAU - Moroff, G
AU  - Moroff G
FAU - Pisciotto, P T
AU  - Pisciotto PT
FAU - Sayers, M
AU  - Sayers M
FAU - Silberstein, L E
AU  - Silberstein LE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Isoantigens)
SB  - IM
MH  - Blood Component Transfusion/adverse effects/*methods
MH  - Cell Separation/*methods
MH  - Fever/etiology/prevention & control
MH  - Humans
MH  - Infections/transmission
MH  - Isoantigens/immunology
MH  - *Leukocytes/immunology/microbiology
RF  - 95
EDAT- 1992/07/15 00:00
MHDA- 1992/07/15 00:01
CRDT- 1992/07/15 00:00
PHST- 1992/07/15 00:00 [pubmed]
PHST- 1992/07/15 00:01 [medline]
PHST- 1992/07/15 00:00 [entrez]
AID - 10.7326/0003-4819-117-2-151 [doi]
PST - ppublish
SO  - Ann Intern Med. 1992 Jul 15;117(2):151-62. doi: 10.7326/0003-4819-117-2-151.